<DOC>
	<DOCNO>NCT00764751</DOCNO>
	<brief_summary>This study compare efficacy safety daily treatment LEO 19123 cream versus Dovonex® cream ( applied twice daily ) versus LEO 19123 cream vehicle alone ( applied twice daily ) subject psoriasis vulgaris . Subject treat 4 week . All subject apply LEO 19123 cream psoriasis lesion leave right side body either Dovonex® cream cream vehicle lesion side .</brief_summary>
	<brief_title>Efficacy Safety LEO 19123 Cream Treatment Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Signed date informed consent obtain prior trial related procedure , include washout . Clinical diagnosis psoriasis vulgaris involve trunk and/or arm and/or legs symmetrical distribution amenable treatment maximum 50 g/week topical medication side body . At Visit 1 , difference right leave side 1 PASI criterion ( redness , thickness scaliness ) . A minimum PASI score extent 2 side least one body region ( i.e . psoriasis affect least 10 % leave right arm , and/or 10 % leave right side trunk , and/or 10 % leave right leg ) . Disease severity grade mild , moderate , severe severe accord Investigator 's global assessment ( IGA ) disease severity side body . The assessment side body . Age 18 year Male subject , female nonchildbearing potential ( i.e . surgically sterile least two year postmenopausal ) Attending hospital outpatient clinic private practice dermatologist Subjects use systemic treatment biological therapy possible effect psoriasis vulgaris within 12 week prior randomisation ( e.g . alefacept , efalizumab , etanercept , infliximab , adalimumab ) Systemic treatment therapy , besides biologics , possible effect psoriasis vulgaris ( e.g. , corticosteroid , retinoids , immunosuppressant ) within 4 week prior randomisation ( inhaled intranasal steroid asthma rhinitis may use ) PUVA Grenz ray therapy within 4 week prior randomisation UVB therapy within 2 week prior randomisation Any topical treatment ( except emollient ) trunk/limbs ( except flexure ) within 2 week prior randomisation Topical treatment relevant skin disorder face flexure ( e.g. , facial flexural psoriasis , eczema ) potent potent ( WHO group IIIIV ) corticosteroid , vitamin D analogue retinoids within 2 week prior randomisation Topical treatment relevant skin disorder scalp ( e.g . scalp psoriasis ) potent ( WHO group IV ) corticosteroid , vitamin D analogue retinoids within 2 week prior randomisation Planned initiation , change concomitant medication could affect psoriasis vulgaris ( e.g. , beta blocker , ACE inhibitor , antimalaria drug , lithium ) within 2 week prior randomisation Subjects receive treatment nonmarketed drug substance ( i.e. , agent yet make available clinical use follow registration ) within 4week period prior randomisation Subjects current participation interventional clinical trial Subjects follow condition present treatment area : eczematous skin , atopic dermatitis , clinical infection , ulcer wound Subjects history serious allergy , allergic skin rash sensitivity component investigational product formulation test Subjects positive hepatitis B , C HIV Known suspect severe renal insufficiency severe hepatic disorder Known suspected disorder calcium metabolism associate hypercalcaemia Current diagnosis erythrodermic , exfoliative , guttate pustular psoriasis Planned exposure sun study may affect psoriasis vulgaris ( i.e. , normal lifestyle outdoor activity permit deliberate exposure sunlight artificial ultraviolet light avoid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>